SCHEMBL1542741

SCHEMBL1542741

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc(NC(=O)c2ccccc2)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 2/20 0.44
AURKA O14965 1/20 0.44
TTK P33981 1/20 0.44
AURKB Q96GD4 1/20 0.44
INCENP Q9NQS7 1/20 0.44
BTK Q06187 1/20 0.44
KIT P10721 1/20 0.43
SRC P12931 1/20 0.43
FLT3 P36888 1/20 0.43
PARP1 P09874 3/20 0.42
ABL1 P00519 1/20 0.42
PPARG P37231 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HDAC2 Q92769 2/20 0.40
NPC1 O15118 1/20 0.40
GLA P06280 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP3 P42574 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2126941 0.86 CYP3A4 (0.53) ITKBTKKITSRCFLT3
SCHEMBL1542657 0.85 CYP3A4 (0.49) ITKAURKATTKAURKBINCENP
SCHEMBL1542748 0.77 CYP3A4 (0.47) ITKBTKKITSRCFLT3
SCHEMBL2128418 0.75 CYP3A4 (0.49) ITKBTKKITSRCFLT3
SCHEMBL1543460 0.75 CYP3A4 (0.44) ITKBTKKITSRCFLT3
SCHEMBL1542911 0.75 CYP3A4 (0.49) ITKBTKKITSRCFLT3
SCHEMBL1542446 0.74 CYP3A4 (0.48) ITKBTKKITSRCFLT3
SCHEMBL1542369 0.73 CYP3A4 (0.65) BTKABL1NR1H4ALDH1A1MAPK1
SCHEMBL2127623 0.73 CYP3A4 (0.53) BTKABL1ALDH1A1CYP3A4
SCHEMBL1543037 0.73 CYP3A4 (0.49) ITKAURKATTKAURKBINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B ITK 4332/4885AURKA 2227/4885TTK 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.